Project publications

  1. Appelman MD, Chakraborty A, Protzer U, McKeating JA and van de Graaf, SFJ. (2017).
    N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.
    Plos ONE,
  1. Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. (2016).
    Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.
    J Virol. 90, 6387-400.
  1. Baumert TF, Jühling F, Ono A, Hoshida Y. (2017).
    Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.
    BMC Med. 5(1):52.
  1. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A.(2016).
    Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut. 66/7, 1286-1296.
  1. Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. (2017).
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. pii: gutjnl-2016-312577. [Epub ahead of print].
  1. Colpitts CC, Lupberger J, Baumert TF. (2016).
    Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesis.
    Proc Natl Acad Sci U S A. 13(27), 7298-300.
  1. Colpitts CC, Baumert TF. (2017).
    SMAD about hepatitis C virus cell entry and liver disease.
    Gastroenterology 152(1), 21-23.
  1. Colpitts CC, Baumert TF. (2017).
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 67(2):211-213.
  1. Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. (2017).
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 66(5), 896-907.
  1. Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJO, McKeating JA. (2017).
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 66, 919-929. Epub 2017 Jan 23.
  1. Gonçalves-Carneiro D, McKeating JA and Bailey D. (2017).
    The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.
    J Virology, 91/7, e02255-16.
  1. Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P,
    Pietschmann T, Brown RJ. (2017).
    Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
    Antiviral Research 139, 129-137.
  1. Marianna Hösel, Maria Quasdorff, Marc Ringelhan, Hamid Kashkar, Svenja Debey-Pascher, Martin F. Sprinzl, Jan-Hendrik Bockmann, Silke Arzberger, Dennis Webb, Gesa von Olshausen, Achim Weber, Joachim L. Schultze, Hildegard Büning, Mathias Heikenwalder and
    Ulrike Protzer. (2017).
    Hepatitis B virus activates signal transducer and activator of transcription 3 supporting hepatocyte survival and virus replication.
    Cellular and Molecular Gastroenterology and Hepatology (in press).
  1. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I,
    Llovet JM. (2017).
    Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    J Hepatol. 66/6, 1166-1172.
  1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. (2016).
    Hepatocellular carcinoma.
    Nat Rev Dis Primers. 2:16018.
  1. Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O. (2017).
    Plasmodium P36 determines host cell receptor usage during sporozoite invasion.
    eLife. 6. pii: e25903.
  1. Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. (2016).
    IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in
    Experimental Models.

    Gastroenterology 151(6):1192-1205.
  1. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. (2017).
    Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    J Hepatol. 66(5):952-961.
  1. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. (2016).
    Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
    Clin Cancer Res. 22(2):291-300.
  1. Ringelhan, M, McKeating JA and Protzer U. (2017).
    Viral hepatitis and Cancer.
    Phil Trans Royal Society, In press.
  1. Sia,D., Jiao, Y., Martinez-Quetglas, I., Kuchuk,O., Villacorta-Martin, O., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S.N., Mazzaferro, V., Esteller, M., Friedman, S.L., Schwartz, M., Villanueva, A., Llovet, J.M. (2017).
    Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Gastroenterology pii: S0016-5085(17)35741-4. [Epub ahead of print].
  1. Sia D, Villanueva A, Friedman SL, Llovet JM. (2017).
    Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Gastroenterology 152:745-761. doi: 10.1053/j.gastro.2016.11.048. PMID: 28043904.
  1. Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. (2017).
    Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results.
    Eur Radiol doi: 10.1007/s00330-017-4844-6.
  1. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L,  Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé  M, Domingo-Domenech J, Villanueva A, Llovet JM. (2017).
    Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut Mar;66(3):530-540.
  1. Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF,
    Lupberger J. (2017).
    miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270. (Epub ahead of print).
  1. Verrier ER, Colpitts CC, Zona L, Bach C, Heydmann L, Xiao F, Thumann C, Schuster C, Sureau C, McKeating JA, Hoshida Y, Zeisel MB and Baumert TF. (2017).
    Solute carrier NTCP regulates expression of innate antiviral immune responses targeting viral cell entry into hepatocytes.
    Cell Reports 17:1357- 1368.
  1. Verrier ER, Schuster C, Baumert TF. (2016).
    Advancing hepatitis B virus entry inhibitors.
    J. Hepatol. 66(4), 677-679.
  1. Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E. (2016).
    Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.
    Sci Rep. 6, 35230.